Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF), the commercial-stage biotech company, has started administering its groundbreaking short-course peanut allergy vaccine candidate, VLP Peanut, to phase I PROTECT trial patients.
The first-of-its-kind study aims to evaluate the safety, tolerability and preliminary efficacy of VLP Peanut in both healthy and peanut-allergic adults.
The company's proprietary vaccine utilises cutting-edge virus-like particle (VLP) technology.
This innovative approach enhances the body's immune response by making the peanut allergen resemble an inactive virus, potentially offering a new solution for peanut allergy sufferers.